{"nctId":"NCT04233879","briefTitle":"Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)","startDateStruct":{"date":"2020-02-28","type":"ACTUAL"},"conditions":["HIV-1 Infection"],"count":599,"armGroups":[{"label":"Group 1: DOR/ISL","type":"EXPERIMENTAL","interventionNames":["Drug: DOR/ISL","Drug: Placebo to BIC/FTC/TAF"]},{"label":"Group 2: BIC/FTC/TAF","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: BIC/FTC/TAF","Drug: Placebo to DOR/ISL"]}],"interventions":[{"name":"DOR/ISL","otherNames":["MK-8591A","Doravirine/islatravir"]},{"name":"BIC/FTC/TAF","otherNames":["Bictegravir/emtricitabine/tenofovir alafenamide"]},{"name":"Placebo to BIC/FTC/TAF","otherNames":[]},{"name":"Placebo to DOR/ISL","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Is human immunodeficiency virus type 1 (HIV-1) positive\n* Is naïve to antiretroviral therapy (ART) defined as having received ≤10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection including prevention of mother-to-child transmission up to 1 month prior to screening.\n* A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: 1) Is not a woman of childbearing potential (WOCBP); 2) Is a WOCBP and using an acceptable contraceptive method, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis); 3) A WOCBP must have a negative highly sensitive pregnancy test (\\[urine or serum\\] as required by local regulations) within 24 hours before the first dose of study intervention; 4) If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required\n\nExclusion Criteria:\n\n* Has HIV-2 infection\n* Has hypersensitivity or other contraindication to any of the components of the study interventions as determined by the investigator\n* Has an active diagnosis of hepatitis due to any cause, including active HBV infection (defined as hepatitis B surface antigen \\[HBsAg\\]-positive or hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\]-positive)\n* Has a history of malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or cutaneous Kaposi's sarcoma\n* Has a history or current evidence of any condition (including active tuberculosis infection), therapy, laboratory abnormality or other circumstance (including drug or alcohol use or dependence) that might, in the opinion of the investigator, confound the results of the study or interfere with the participant's participation for the full duration of the study\n* Has been treated for a viral infection other than HIV-1, such as hepatitis B, with an agent that is active against HIV-1\n* Is taking or is anticipated to require systemic immunosuppressive therapy, immune modulators, or any prohibited therapy from 45 days prior to Day 1 through the study intervention period\n* Is currently participating in or has participated in a clinical study with an investigational compound or device from 45 days prior to Day 1 through the study intervention period\n* Has a documented or known virologic resistance to any approved HIV-1 reverse transcriptase inhibitor, or any study intervention\n* Has exclusionary laboratory values within 45 days prior to Day 1\n* Is female and is expecting to conceive or donate eggs at any time during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48","description":"HIV-1 RNA levels in blood samples taken at each visit were measured by the Abbott Real Time polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of 40 copies/mL. The percentage of participants with HIV-1 RNA \\<50 copies/mL at Week 48 was presented using the FDA Snapshot missing data approach.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null},{"groupId":"OG001","value":"88.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Experienced an Adverse Event (AE) up to Week 48","description":"An AE is any untoward medical occurrence in a study participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The percentage of participants who experience an AE was reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.6","spread":null},{"groupId":"OG001","value":"86.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Discontinued Study Treatment Due to an AE up to Week 48","description":"An AE is any untoward medical occurrence in a study participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The percentage of participants who discontinued study treatment due to an AE were reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":null},{"groupId":"OG001","value":"3.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96","description":"The percentage of participants with HIV-1 RNA \\<50 copies/mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The percentage of participants with HIV-1 RNA \\<50 copies/mL at Week 96 will be presented using the FDA Snapshot missing data approach.","classes":[]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 144","description":"The percentage of participants with HIV-1 RNA \\<50 copies/mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The percentage of participants with HIV-1 RNA \\<50 copies/mL at Week 144 will be presented using the FDA Snapshot missing data approach.","classes":[]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 48","description":"The percentage of participants with HIV-1 RNA \\<40 copies/mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The percentage of participants with HIV-1 RNA \\<40 copies/mL at Week 48 will be presented using the FDA Snapshot missing data approach.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.6","spread":null},{"groupId":"OG001","value":"86.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 48","description":"The percentage of participants with HIV-1 RNA \\<200 copies/mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The percentage of participants with HIV-1 RNA \\<200 copies/mL at Week 48 will be presented using the FDA Snapshot missing data approach.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.6","spread":null},{"groupId":"OG001","value":"88.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 96","description":"The percentage of participants with HIV-1 RNA \\<40 copies/mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The percentage of participants with HIV-1 RNA \\<40 copies/mL at Week 96 will be presented using the FDA Snapshot missing data approach.","classes":[]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 96","description":"The percentage of participants with HIV-1 RNA \\<200 copies/mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The percentage of participants with HIV-1 RNA \\<200 copies/mL at Week 96 will be presented using the FDA Snapshot missing data approach.","classes":[]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 144","description":"The percentage of participants with HIV-1 RNA \\<40 copies/mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The percentage of participants with HIV-1 RNA \\<40 copies/mL at Week 144 will be presented using the FDA Snapshot missing data approach.","classes":[]},{"type":"SECONDARY","title":"Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 144","description":"The percentage of participants with HIV-1 RNA \\<200 copies/mL will be determined. The central laboratory will measure plasma HIV-1 RNA using an Abbott Real Time PCR assay with a LLOD of 40 copies/mL. The percentage of participants with HIV-1 RNA \\<200 copies/mL at Week 144 will be presented using the FDA Snapshot missing data approach.","classes":[]},{"type":"SECONDARY","title":"Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 48","description":"Plasma CD4+ T-cell count was measured in cells/mm\\^3 for baseline and 48 weeks by a central laboratory. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in CD4+ T-cell count at Week 48 was presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"182.4","spread":null},{"groupId":"OG001","value":"233.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 96","description":"Plasma CD4+ T-cell count will be measured in cells/mm\\^3 for baseline and 96 weeks by a central laboratory. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in CD4+ T-cell count at Week 96 will be presented.","classes":[]},{"type":"SECONDARY","title":"Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 144","description":"Plasma CD4+ T-cell count will be measured in cells/mm\\^3 for baseline and 144 weeks by a central laboratory. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in CD4+ T-cell count at Week 144 will be presented.","classes":[]},{"type":"SECONDARY","title":"Incidence of Viral Resistance-Associated Substitutions (RASs) at Week 48","description":"RASs was defined as participants with confirmed HIV-1 RNA ≥200 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrated RASs at Week 48 was presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Viral RASs at Week 96","description":"RASs was defined as participants with confirmed HIV-1 RNA ≥200 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrate viral RASs at Week 96 will be presented.","classes":[]},{"type":"SECONDARY","title":"Incidence of Viral RASs at Week 144","description":"RASs was defined as participants with confirmed HIV-1 RNA ≥200 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrate viral RASs at Week 144 will be presented.","classes":[]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight at Week 48","description":"Body weight was measured at baseline and at Week 48. Baseline measurements were defined as the Day 1 value of each participant. The change from baseline in body weight at Week 48 was presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.45","spread":null},{"groupId":"OG001","value":"3.32","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight at Week 96","description":"Body weight was measured at baseline and at Week 96. Baseline measurements were defined as the Day 1 value of each participant. The change from baseline in body weight at Week 96 will be presented.","classes":[]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight at Week 144","description":"Body weight was measured at baseline and at Week 144. Baseline measurements were defined as the Day 1 value of each participant. The change from baseline in body weight at Week 144 will be presented.","classes":[]},{"type":"SECONDARY","title":"Percentage of Participants Who Experienced an Adverse Event (AE) up to Week 156","description":"An AE is any untoward medical occurrence in a study participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The percentage of participants who experience an AE will be reported.","classes":[]},{"type":"SECONDARY","title":"Percentage of Participants Who Discontinued Study Treatment Due to an AE up to Week 156","description":"An AE is any untoward medical occurrence in a study participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The percentage of participants who discontinued study treatment due to an AE will be reported.","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":298},"commonTop":["COVID-19","Headache","Lymphocyte count decreased","Diarrhoea","Accidental overdose"]}}}